ImmuCell Appoints New Directors, Restructures Board
Analysis based on 7 articles · First reported Apr 13, 2026 · Last updated Apr 13, 2026
The appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board of Directors of ImmuCell, along with the shift to a more independent board structure, are expected to positively impact investor confidence in ImmuCell's strategic direction and corporate governance. This move could lead to improved innovation and operational efficiency, potentially boosting the company's stock performance.
ImmuCell announced the appointment of Dr. Gilles Guillemette and Dr. Anthony DiMarco to its Board of Directors, effective April 15, 2026. Concurrently, ImmuCell is transitioning to a 7-person Board of Directors, comprising six Independent Directors and the CEO, and establishing a new Strategy and Technology Committee. Dr. Gilles Guillemette brings over 30 years of executive experience in animal health therapeutics, having held positions at Elanco, Bayer, Henry Schein, Chewy, and Trupanion. Dr. Anthony DiMarco offers four decades of scientific leadership from human and animal health biologics companies, including Abbott Laboratories and Abbott Laboratories. This restructuring also involves the retirement of Bryan Gathagan, Michael Brito, Bobbi Brockmann, and Timothy Fiori from the board, with Ms. Brockmann and Mr. Fiori continuing in their executive roles. The changes aim to bolster ImmuCell's innovation strategy, improve manufacturing processes, and enhance corporate governance.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard